Trial Profile
A Worldwide, Phase I, Dose-Escalating Study of Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs V 520 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2009 Planned end date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 10 Mar 2009 Planned patient number (435) added as reported by ClinicalTrials.gov.